[Pyoderma gangrenosum aggravated by GM-CSF administration].
Perrot
J L
JL
Service de Dermatologie, CHU, Saint-Etienne, Hôpital Nord, Saint-Priest-en-Jarez.
Benoit
F
F
Segault
D
D
Jaubert
J
J
Guyotat
D
D
Claudy
A
A
D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D009503:Neutropenia / Q000188:drug therapy / Q000503:physiopathology; D017511:Pyoderma Gangrenosum / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology
D016178:Granulocyte-Macrophage Colony-Stimulating Factor
Pyoderma gangrenosum aggravé par administration de GM-CSF.